Ocugen licenses OCU400 to Celairis for Australia, New Zealand and ASEAN markets
Celairis will handle regulatory filings and commercialization of the retinitis pigmentosa gene therapy across the region while Ocugen retains manufacturing rights and collects royalties and profit share.
SEC filing